A blistering November rally in Indian equities has set a demanding backdrop as traders return to their screens for a subdued start to the week.
Small-cap stocks have surged more than 9% since the month began, while mid-caps have added over 7%, reflecting broad-based appetite for risk assets across the subcontinent.
The larger benchmarks have also delivered strong gains, with the NSE Nifty 50 and the Sensex each climbing more than 3% through November so far.
Last week alone, the Nifty 50 posted a 1.58% advance, its strongest weekly performance in two months, while the Sensex added 1.37% over the same period.
Despite that momentum, Monday’s session looks set to begin quietly, with the GIFT Nifty sliding 0.1% to 19,794.50 as of 7:59 a.m. IST.
Expectations that the U.S. Federal Reserve would hold off on further rate increases have been a primary engine behind the November gains across Indian markets.
Investors are now waiting on the minutes from the Fed’s most recent policy meeting, which could either reinforce or complicate that rate-pause thesis.
Across the wider region, MSCI’s broadest index covering Asia-Pacific equities outside Japan edged 0.3% higher, suggesting tempered but positive sentiment among global investors.
SMC Global Securities offered an optimistic assessment of where domestic markets are headed, writing that “market is expected to continue its upward movement driven by robust macro data and diminishing global concerns.”
On the corporate front, Australian exchange operator ASX Ltd struck an agreement with Tata Consultancy Services to design and build a replacement for its trading, clearing, and settlement infrastructure.
The TCS deal underscores the growing international demand for Indian technology firms as partners in rebuilding critical financial market systems worldwide.
Shares of Cipla are also drawing attention from traders as the session gets underway, adding a pharmaceutical dimension to Monday’s market watch list.
